Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Orserdu (elacestrant)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

DRI Healthcare, Menarini, Radius

Drug class:

Selective estrogen receptor degrader

Related drugs:

ER positive + ESR1 mutation	HER2 Negative Breast Cancer	ER positive + ESR1 mutation	HER2 Negative Breast Cancer	elacestrant Sensitive: A1 - Approval Menarini Press Release - 1 week (New A1) elacestrant Sensitive : A1 Menarini Press Release - 1wk	elacestrant Sensitive: A1 - Approval Menarini Press Release - 1 week elacestrant Sensitive : A1 Menarini Press Release - 1 week - (New A1)
ESR1 mutation + HR positive	HER2 Negative Breast Cancer	ESR1 mutation + HR positive	HER2 Negative Breast Cancer	elacestrant Sensitive: A2 - Guideline elacestrant Sensitive : A2	elacestrant Sensitive: A2 - Guideline elacestrant Sensitive : A2
ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	elacestrant Sensitive: B - Late Trials elacestrant Sensitive : B	elacestrant Sensitive: B - Late Trials elacestrant Sensitive : B
ER positive	Estrogen Receptor Positive Breast Cancer	ER positive	Estrogen Receptor Positive Breast Cancer	elacestrant Sensitive: B - Late Trials elacestrant Sensitive : B	elacestrant Sensitive: B - Late Trials elacestrant Sensitive : B
ER mutation	Estrogen Receptor Positive Breast Cancer	ER mutation	Estrogen Receptor Positive Breast Cancer	elacestrant Sensitive: D – Preclinical elacestrant Sensitive : D	elacestrant Sensitive: D – Preclinical elacestrant Sensitive : D
PIK3CA wild-type+ ESR1 wild-type	Breast Cancer	PIK3CA wild-type+ ESR1 wild-type	Breast Cancer	MEN1611 + elacestrant Sensitive: D – Preclinical MEN1611 + elacestrant Sensitive : D	MEN1611 + elacestrant Sensitive: D – Preclinical MEN1611 + elacestrant Sensitive : D
PIK3CA mutation + ESR1 wild-type	Breast Cancer	PIK3CA mutation + ESR1 wild-type	Breast Cancer	MEN1611 + elacestrant Sensitive: D – Preclinical MEN1611 + elacestrant Sensitive : D	MEN1611 + elacestrant Sensitive: D – Preclinical MEN1611 + elacestrant Sensitive : D
PIK3CA mutation + ESR1 mutation	Breast Cancer	PIK3CA mutation + ESR1 mutation	Breast Cancer	MEN1611 + elacestrant Sensitive: D – Preclinical MEN1611 + elacestrant Sensitive : D	MEN1611 + elacestrant Sensitive: D – Preclinical MEN1611 + elacestrant Sensitive : D